ESR1 and breast carcinoma: In one of the first reports of acquired ESR1 mutations in human breast cancers, Fuqua and coworkers in 1997 described a nonsynonymous mutation in Tyr537 (Y537N) in a study of 30 metastatic breast cancer tumors and implicated this mutation in hormone-independent constitutive activation of the ER [18].